Effectiveness of Lidocaine Injection on Stellate Ganglion in Pediatric Patients With Autism Spectrum Disorder

Launched by MUHAMMAD · Mar 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called a stellate ganglion block in children with Autism Spectrum Disorder (ASD). The main goal is to find out if this treatment can help improve symptoms of autism in young children. In the trial, children aged 3 to 6 who have been diagnosed with ASD will be divided into two groups: one group will receive the stellate ganglion block along with their usual therapy, while the other group will only receive the usual therapy. Researchers will compare the results from both groups using a special assessment tool to see if there are any improvements.

To take part in this trial, children must be between 3 and 6 years old and have a diagnosis of Autism Disorder. They should not have any other serious medical or developmental issues that could affect the study. This trial is not yet recruiting participants, but it aims to provide valuable information about how this treatment may help children with autism. Families considering participation should know that the trial is focused on understanding the potential benefits of this new approach in managing autism symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed as Autistic Disorder.
• • Aged between 3 years old and 6 years old.
• • No contraindications to stellate ganglion block.
• Exclusion Criteria:
• • Other significant physical or neurodevelopmental disorders.
• • Other significant medical conditions